Markers of Prognosis and Response to Therapy in Patients With Metastatic Brain Tumors Undergoing Stereotactic Radiosurgery (SRS)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tracie Granger
- Phone Number: 206-215-2466
- Email: tracie.granger@swedish.org
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98122
- Recruiting
- Swedish Medical Center
-
Contact:
- Tracie Granger
- Phone Number: 206-215-2466
- Email: tracie.granger@swedish.org
-
Principal Investigator:
- Sarah Fouke, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients (>18 yo) with a pathological diagnosis of metastatic brain cancer
- Participants must have >4 tumors felt to require stereotactic radiosurgery
- Karnofsky scale of > 70 at the time of initial treatment
- Age < 80
Exclusion Criteria:
- Karnofsky scale <70
- Age > 80
- Inability to undergo MR imaging studies
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Quantitative measures of overall tumor volume will be performed for each subject at the time of SRS
Time Frame: At the time of SRS
|
At the time of SRS
|
|
Quantitative measures of tumor number will be performed for each subject at the time of SRS
Time Frame: At the time of SRS
|
At the time of SRS
|
|
Overall survival will be measured for each subject (in weeks from SRS to death)
Time Frame: Post-SRS
|
Post-SRS
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Measures of ADC, rCBV, MTT and ktrans will be performed for each treated tumor at treatment and at 6 months following SRS
Time Frame: 6 months post SRS
|
6 months post SRS
|
|
Time to progression (in weeks) will be measured for each treated tumor
Time Frame: Post-SRS
|
Post-SRS
|
|
Diagnosis of progression or radiation necrosis (made on clinical reflection at study's end) will be determined for tumors where diagnosis is in question at 6 and 12 months after SRS
Time Frame: 12 months post-SRS
|
12 months post-SRS
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SRS - Mets
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.